Bleeding In Thrombocytopenia Explained
Bleeding in Thrombocytopenia Explained
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
1,000 participants
Dec 4, 2018
OBSERVATIONAL
Conditions
Summary
Multicenter case cohort study investigating clinical risk factors for clinically relevant bleeding in hemato-oncology patients, as well as bleeding related biomarkers during intensive treatment.
Eligibility
Inclusion Criteria6
- Admission in the hospital. (part A and B)
- Age ≥ 18 years. (part A and B)
- AND:
- Hemato-oncology patient, including MDS and AA, admitted for treatment (chemotherapy, SCT) who is (expected to become) thrombocytopenic with platelet counts of < 50 for expected at least 5 days and who will possibly be treated with one or more prophylactic platelet transfusions. (part A and B)
- OR:
- Hemato-oncology patient who had previous intensive chemotherapy or stem cell transplantation and who is admitted to the hematology ward for disease or treatment related events or complications. (part A only)
Exclusion Criteria1
- Patients with myeloproliferative disorders.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
* Blood withdrawal will be at regular sampling moments, blood can be collected from a central venous catheter or venepuncture procedure. * Blood withdrawal will be performed for a maximum of 10 times per admission, 10 ml per time. * Urine sampling will be for a maximum of 5 times per admission. * Urine can be sampled from a catheter when present, or collected regular.
Questionnaire to investigate a bleeding tendency before diagnosis.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03505086